C74
Conditions
Interventions
Group 1: Major objective of the NB Registry is the collection of key characteristics of patients with refractory or relapsed neuroblastic tumors treated with the ch14.18/CHO antibody and subcutaneous
Sponsors
Universitätsklinikum Tübingen
Eligibility
Sex/Gender
All
Age
No minimum to 21 Years
Inclusion criteria
Inclusion criteria: Patients with metastasized relapsed neuroblastoma after autologous stem cell transplantation (MYC-N positive or negative) Patients with neuroblastoma refractory to standard treatment (MYC-N positive or negative) Patients with MYC-N positive neuroblastoma and localized relapse after autologous stem cell transplantation
Exclusion criteria
Exclusion criteria: For this registry, no exclusion criteria are defined. Each patient meeting the inclusion criteria given above may be registered.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To facilitate counselling of physicians and patients in the treatment of relapsed or refractory high risk neuroblastomas 2. To facilitate long term follow-up of patients with relapsed neuroblastoma, 3. To document late effects of treatment, especially of the allogenic transplantation and the antibody treatment. 4. To provide clinical data for retrospective subgroup analyses | — |
Countries
Austria, China, Germany, Netherlands
Contacts
Public ContactPeter Lang
Universitätsklinikum Tübingen
Outcome results
None listed